Product Code: GVR-4-68038-533-5
Electronic Drug Delivery Systems Market Growth & Trends:
The global electronic drug delivery systems market size is expected to reach USD 20.19 billion by 2030, registering a CAGR of 9.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. Technological advancements allowing easy self-administration technologies, mainly in infusion pumps and auto injectors that help in large-volume and high-viscosity biologic drugs have created a potential market opportunity for the companies. Approvals of novel drug formulations for use in infusion pumps allow a novel treatment option, thereby advancing diabetes care in adults.
In October 2019, Novo Nordisk received the U.S. Food and Drug Administration approval for Fiasp, insulin injection for use in insulin pumps for patients with type 1 and 2 diabetes. Moreover, the innovative wearable infusion pumps allow the patients to wirelessly connect to smartphone apps. This enables healthcare professionals to track patient data and tailor specific therapies as per individual requirements. The aforementioned factors have augmented the demand for electronic drug delivery systems globally. However, automated pumps may have risks of wrong dosage with technical glitches and might lead to adverse drug reactions. This may hinder the market growth.
Electronic Drug Delivery Systems Market Report Highlights:
- Wearable infusion pumps accounted for the largest share of 41.4% in 2024. The growing demand for minimally invasive, user-friendly devices for managing chronic conditions such as diabetes is a key driving factor for wearable infusion pumps in the electronic drug delivery systems market.
- The diabetes segment held the largest market share of 36.4% in 2024 and is expected to grow at the fastest CAGR over the forecast period.
- The retail pharmacies segment dominated the market with the largest revenue share in 2024. The growing demand for convenient home delivery of prescription medications, driven by advancements in digital pharmacy services and fulfillment networks, is a key driving factor for the segment.
- North America electronic drug delivery systems market held the largest share of 44.7% in 2024, which can be attributed to the increasing demand for precise, reliable, and ISO-compliant testing solutions for autoinjectors, ensuring optimal performance and safety in drug delivery devices.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Electronic Drug Delivery Systems Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTLE Analysis
Chapter 4. Electronic Drug Delivery Systems Market: Product Business Analysis
- 4.1. Product Market Share, 2024 & 2030
- 4.2. Product Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 4.4. Wearable Infusion Pumps
- 4.4.1. Wearable infusion pumps market, 2018 - 2030 (USD Million)
- 4.5. Auto Injectors
- 4.5.1. Auto injectors devices market, 2018 - 2030 (USD Million)
- 4.6. Injection Pens
- 4.6.1. Injection pens market, 2018 - 2030 (USD Million)
- 4.7. Inhalers
- 4.7.1. Inhalers market, 2018 - 2030 (USD Million)
Chapter 5. Electronic Drug Delivery Systems Market: Application Business Analysis
- 5.1. Application Market Share, 2024 & 2030
- 5.2. Application Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
- 5.4. Diabetes
- 5.4.1. Diabetes market, 2018 - 2030 (USD Million)
- 5.5. Cardiovascular Disease
- 5.5.1. Cardiovascular disease market, 2018 - 2030 (USD Million)
- 5.6. Respiratory disorders
- 5.6.1. Respiratory disorders market, 2018 - 2030 (USD Million)
- 5.7. Multiple sclerosis
- 5.7.1. Multiple sclerosis market, 2018 - 2030 (USD Million)
- 5.8. Others
- 5.8.1. Others market, 2018 - 2030 (USD Million)
Chapter 6. Electronic Drug Delivery Systems Market: Distribution Channel Business Analysis
- 6.1. Distribution Channel Market Share, 2024 & 2030
- 6.2. Distribution Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
- 6.4. Hospital Pharmacies
- 6.4.1. Hospital pharmacies market, 2018 - 2030 (USD Million)
- 6.5. Retail Pharmacies
- 6.5.1. Retail pharmacies market, 2018 - 2030 (USD Million)
- 6.6. Online Pharmacies
- 6.6.1. Online pharmacies market, 2018 - 2030 (USD Million)
Chapter 7. Electronic Drug Delivery Systems Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
- 7.4. North America
- 7.4.1. North America electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Regulatory framework
- 7.4.2.3. Competitive insights
- 7.4.2.4. U.S. electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Regulatory framework
- 7.4.3.3. Competitive insights
- 7.4.3.4. Canada electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key country dynamics
- 7.4.4.2. Regulatory framework
- 7.4.4.3. Competitive insights
- 7.4.4.4. Mexico electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5. Europe
- 7.5.1. Europe electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework
- 7.5.2.3. Competitive insights
- 7.5.2.4. UK electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework
- 7.5.3.3. Competitive insights
- 7.5.3.4. Germany electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Regulatory framework
- 7.5.4.3. Competitive insights
- 7.5.4.4. France electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Regulatory framework
- 7.5.5.3. Competitive insights
- 7.5.5.4. Italy electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Regulatory framework
- 7.5.6.3. Competitive insights
- 7.5.6.4. Spain electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key country dynamics
- 7.5.7.2. Regulatory framework
- 7.5.7.3. Competitive insights
- 7.5.7.4. Denmark electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key country dynamics
- 7.5.8.2. Regulatory framework
- 7.5.8.3. Competitive insights
- 7.5.8.4. Sweden electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key country dynamics
- 7.5.9.2. Regulatory framework
- 7.5.9.3. Competitive insights
- 7.5.9.4. Norway electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework
- 7.6.2.3. Competitive insights
- 7.6.2.4. Japan electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Regulatory framework
- 7.6.3.3. Competitive insights
- 7.6.3.4. China electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Regulatory framework
- 7.6.4.3. Competitive insights
- 7.6.4.4. India electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Regulatory framework
- 7.6.5.3. Competitive insights
- 7.6.5.4. Australia electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Regulatory framework
- 7.6.6.3. Competitive insights
- 7.6.6.4. South Korea electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key country dynamics
- 7.6.7.2. Regulatory framework
- 7.6.7.3. Competitive insights
- 7.6.7.4. Thailand electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework
- 7.7.2.3. Competitive insights
- 7.7.2.4. Brazil electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Regulatory framework
- 7.7.3.3. Competitive insights
- 7.7.3.4. Argentina electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8. MEA
- 7.8.1. MEA electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Regulatory framework
- 7.8.2.3. Competitive insights
- 7.8.2.4. South Africa electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key country dynamics
- 7.8.3.2. Regulatory framework
- 7.8.3.3. Competitive insights
- 7.8.3.4. Saudi Arabia electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key country dynamics
- 7.8.4.2. Regulatory framework
- 7.8.4.3. Competitive insights
- 7.8.4.4. UAE electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key country dynamics
- 7.8.5.2. Regulatory framework
- 7.8.5.3. Competitive insights
- 7.8.5.4. Kuwait electronic drug delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Bayer AG
- 8.5.1.1. Overview
- 8.5.1.2. Financial performance
- 8.5.1.3. Product benchmarking
- 8.5.1.4. Strategic initiatives
- 8.5.2. Gerresheimer AG
- 8.5.2.1. Overview
- 8.5.2.2. Financial performance
- 8.5.2.3. Product benchmarking
- 8.5.2.4. Strategic initiatives
- 8.5.3. Medtronic
- 8.5.3.1. Overview
- 8.5.3.2. Financial performance
- 8.5.3.3. Product benchmarking
- 8.5.3.4. Strategic initiatives
- 8.5.4. Elcam Medical
- 8.5.4.1. Overview
- 8.5.4.2. Financial performance
- 8.5.4.3. Product benchmarking
- 8.5.4.4. Strategic initiatives
- 8.5.5. Novo Nordisk A/S
- 8.5.5.1. Overview
- 8.5.5.2. Financial performance
- 8.5.5.3. Product benchmarking
- 8.5.5.4. Strategic initiatives
- 8.5.6. Insulet Corporation
- 8.5.6.1. Overview
- 8.5.6.2. Financial performance
- 8.5.6.3. Product benchmarking
- 8.5.6.4. Strategic initiatives
- 8.5.7. Unilife Corporation (Amgen Inc.)
- 8.5.7.1. Overview
- 8.5.7.2. Financial performance
- 8.5.7.3. Product benchmarking
- 8.5.7.4. Strategic initiatives
- 8.5.8. BD
- 8.5.8.1. Overview
- 8.5.8.2. Financial performance
- 8.5.8.3. Product benchmarking
- 8.5.8.4. Strategic initiatives